Parkinson Alzheimer Medications NCLEX — Levodopa Donepezil Memantine Nursing | NurseNest

Parkinson Alzheimer Medications NCLEX — Levodopa Donepezil Memantine Nursing | NurseNest

Key Concepts

Neurologic Disease Drug Overview

Parkinson's Disease Agents: | Drug | Class | Key Points | |---|---|---| | Levodopa/carbidopa (Sinemet) | DA precursor + AADC inhibitor | Gold standard; wearing off; dyskinesias | | Pramipexole (Mirapex), ropinirole | Dopamine agonist | Less effective; impulse control problems | | Selegiline, rasagiline | MAO-B inhibitor | Neuroprotective; serotonin syndrome risk with SSRIs | | Entacapone (Comtan) | COMT inhibitor | Prolongs levodopa effect; diarrhea | | Amantadine | NMDA antagonist | Dyskinesia treatment; mild antiparkinsonian | Alzheimer's Disease Agents: | Drug | Class | Indication | |---|---|---| | Donepezil (Aricept) | AChE inhibitor | All stages | | Rivastigmine (Exelon) | AChE inhibitor | Mild-moderate; also Parkinson's dementia | | Galantamine (Razadyne) | AChE inhibitor | Mild-moderate | | Memantine (Namenda) | NMDA antagonist | Moderate-severe | | Aducanumab (Aduhelm) | Anti-amyloid mAb | Controversial; FDA approval via accelerated pathway | On the exam, writers often pair stable-sounding options with unstable data—notice the mismatch before you commit. If the stem names a license or role, reread that line; scope errors are classic trap answers even when the...

Levodopa/Carbidopa — Core Content

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Signs and Symptoms

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Red Flags / Danger Signs

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Nursing Considerations

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Clinical Pearls & Exam Tips

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Client Education

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Your exam focus

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Next steps

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Unlock full lesson + practice questions

8 more sections with scenarios, priorities, and review drills.

Start free trial Sign in

Retention & exam readiness

Clinical pearls, traps, safety priorities, quick recall, and related concepts live here so the main lesson stays calm and uninterrupted.

Review after learning, not during it.

Topic overview

NCLEX Parkinson's and Alzheimer's pharmacology: levodopa/carbidopa, dopamine agonists, donepezil, rivastigmine, memantine — adverse effects, nursing priorities.

Clinical reasoning

For Parkinson's Disease and Alzheimer's Medications, connect the assessment cue to the immediate risk before selecting an action for RN. Start with stability, ABCs, neurologic change, medication risk, infection risk, and scope of practice. Then decide whether the safest next step is assess, intervene, escalate, teach, or evaluate response.

Patient safety implications

A missed priority in Parkinson's Disease and Alzheimer's Medications can delay recognition of deterioration or allow preventable harm to continue. Protect the client first by verifying abnormal cues, using ordered precautions, escalating unstable findings, and reassessing after intervention.

Example application

Next study step

Continue Your Learning

Finish the lesson first, then choose a focused activity to apply what you just reviewed.

Practice QuestionsApply this topic with board-style rationales.Open activity

Continue studying

Review Flashcards Practice Related Questions Continue Weak Area Recovery Recommended Next Lesson Take A Readiness Quiz

Practice this topic

Flashcards (same topic)Topic practice tests Adaptive practice test (weak areas)← All lessons

Sign in to save progress on this lesson.

Neurologic Disease Drug Overview: Parkinson's Disease Agents: | Drug | Class | Key Points | |---|---|---| | Levodopa/carbidopa (Sinemet) | DA precursor + AADC inhibitor | Gold standard; wearing off; dyskinesias | | Pramipexole (Mirapex), ropinirole | Dopamine agonist | Less effective; impulse control problems | | Selegiline, rasagiline | MAO-B inhibitor | Neuroprotective; serotonin syndrome risk with SSRIs | | Entacapone (Comtan) | COMT inhibitor | Prolongs levodopa effect; diarrhea | | Amantadine | NMDA antagonist | Dyskinesia treatment; mild antiparkinsonian | Alzheimer's Disease Agents: | Drug | Class | Indication | |---|---|---| | Donepezil (Aricept) | AChE inhibitor | All stages | | Rivastigmine (Exelon) | AChE inhibitor | Mild-moderate; also Parkinson's dementia | | Galantamine (Razadyne) | AChE inhibitor | Mild-moderate | | Memantine (Namenda) | NMDA antagonist | Moderate-severe | | Aducanumab (Aduhelm) | Anti-amyloid mAb | Controversial; FDA approval via accelerated pathway | On the exam, writers often pair stable-sounding options with unstable data—notice the mismatch before you commit.

Neurologic Disease Drug Overview: Parkinson's Disease Agents: | Drug | Class | Key Points | |---|---|---| | Levodopa/carbidopa (Sinemet) | DA precursor + AADC inhibitor | Gold standard; wearing off; dyskinesias | | Pramipexole (Mirapex), ropinirole | Dopamine agonist | Less effective; impulse control problems | | Selegiline, rasagiline | MAO-B inhibitor | Neuroprotective; serotonin syndrome risk with SSRIs | | Entacapone (Comtan) | COMT inhibitor | Prolongs levodopa effect; diarrhea | | Amantadine | NMDA antagonist | Dyskinesia treatment; mild antiparkinsonian | Alzheimer's Disease Agents: | Drug | Class | Indication | |---|---|---| | Donepezil (Aricept) | AChE inhibitor | All stages | | Rivastigmine (Exelon) | AChE inhibitor | Mild-moderate; also Parkinson's dementia | | Galantamine (Razadyne) | AChE inhibitor | Mild-moderate | | Memantine (Namenda) | NMDA antagonist | Moderate-severe | | Aducanumab (Aduhelm) | Anti-amyloid mAb | Controversial; FDA approval via accelerated pathway | On the exam, writers often pair stable-sounding options with unstable data—notice the mismatch before you commit.

Neurologic Disease Drug Overview: Parkinson's Disease Agents: | Drug | Class | Key Points | |---|---|---| | Levodopa/carbidopa (Sinemet) | DA precursor + AADC inhibitor | Gold standard; wearing off; dyskinesias | | Pramipexole (Mirapex), ropinirole | Dopamine agonist | Less effective; impulse control problems | | Selegiline, rasagiline | MAO-B inhibitor | Neuroprotective; serotonin syndrome risk with SSRIs | | Entacapone (Comtan) | COMT inhibitor | Prolongs levodopa effect; diarrhea | | Amantadine | NMDA antagonist | Dyskinesia treatment; mild antiparkinsonian | Alzheimer's Disease Agents: | Drug | Class | Indication | |---|---|---| | Donepezil (Aricept) | AChE inhibitor | All stages | | Rivastigmine (Exelon) | AChE inhibitor | Mild-moderate; also Parkinson's dementia | | Galantamine (Razadyne) | AChE inhibitor | Mild-moderate | | Memantine (Namenda) | NMDA antagonist | Moderate-severe | | Aducanumab (Aduhelm) | Anti-amyloid mAb | Controversial; FDA approval via accelerated pathway | On the exam, writers often pair stable-sounding options with unstable data—notice the mismatch before you commit.

Neurologic Disease Drug Overview: Parkinson's Disease Agents: | Drug | Class | Key Points | |---|---|---| | Levodopa/carbidopa (Sinemet) | DA precursor + AADC inhibitor | Gold standard; wearing off; dyskinesias | | Pramipexole (Mirapex), ropinirole | Dopamine agonist | Less effective; impulse control problems | | Selegiline, rasagiline | MAO-B inhibitor | Neuroprotective; serotonin syndrome risk with SSRIs | | Entacapone (Comtan) | COMT inhibitor | Prolongs levodopa effect; diarrhea | | Amantadine | NMDA antagonist | Dyskinesia treatment; mild antiparkinsonian | Alzheimer's Disease Agents: | Drug | Class | Indication | |---|---|---| | Donepezil (Aricept) | AChE inhibitor | All stages | | Rivastigmine (Exelon) | AChE inhibitor | Mild-moderate; also Parkinson's dementia | | Galantamine (Razadyne) | AChE inhibitor | Mild-moderate | | Memantine (Namenda) | NMDA antagonist | Moderate-severe | | Aducanumab (Aduhelm) | Anti-amyloid mAb | Controversial; FDA approval via accelerated pathway | On the exam, writers often pair stable-sounding options with unstable data—notice the mismatch before you commit.